Iclusig (Ponatinib HCl) Patent Expiration, LOE Window & CMS Spending

Iclusig (Ponatinib HCl) by Takeda: FDA Orange Book core substance LOE 2033-12-12, 0 AB generics, $238.4M 2024 CMS Part D & Medicaid spend, and 24 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN203469 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-12-12
Last Listed Patent or Exclusivity Date2033-12-12
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$238.4M
2024 Medicare Part D Spend$159.5M
2024 Medicaid Spend$78.8M
Reported Wholesale Price Change (CA SB 17)24 WAC filings (max 24.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.